Halozyme Therapeutics Inc (HALO)

[maumar]

There has been some progress in the clinic and they have some good products to look forward to, but the pipeline is getting smaller and smaller. I believe we used to have 12 products in development, then 10 even as recently as perhaps two quarters ago, and now seven. We are not adding but losing shots on goal. As I feared, Amgen did discontinue development of Tepezza and the whole partnership.

I think you are right we are a long way to $59 and we will not get there in the near or even medium term without significant new deals or acquisitions imho. There seems to be no attempt to deal with the market's concern about the "after" Enhanze.

"We currently have a robust pipeline with seven exciting products in development. This reflects amivantamab moving to Wave 3 based on the updated potential launch timing and Amgen's decision to not move forward with a subcutaneous version of TEPEZZA with ENHANZE. Johnson & Johnson has also made the decision to not proceed with rilpivirine subcutaneous."